Laboratory Corporation of America
Laboratory Corporation of America was paid $21K by Medicaid between Dec 2020 and Jan 2024, across 3 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 54% of everything it billed.
FEDERAL WAY, WA 98003
Next to other Clinical Medical Laboratory providers in Washington
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 48 | $4K | |
| 2021 | 95 | $7K | |
| 2022 | 52 | $2K | |
| 2023 | 188 | $7K | |
| 2024incomplete | 13 | $465.60 |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 54% | 143 | 142 | $11K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 44% | 241 | 227 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 12 | 12 | $278.28 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.